Drugs & Targets FDA publishes final guidance on drug development for AML October 21, 2022Vol.48 No.38
Drugs & Targets FDA publishes draft guidance on characterizing, collecting, and reporting immune-mediated adverse reactions October 21, 2022Vol.48 No.38
Drugs & Targets FDA publishes draft guidance on tissue agnostic drug development in oncology October 21, 2022Vol.48 No.38
Drugs & Targets Pluvicto receives positive CHMP opinion for prostate cancer October 21, 2022Vol.48 No.38
Drugs & Targets Libtayo receives positive CHMP opinion for advanced cervical cancer October 21, 2022Vol.48 No.38
Drugs & Targets HOOKIPA, Roche form collaboration to develop arenaviral immunotherapy for KRAS-mutated cancers October 21, 2022Vol.48 No.38
Drugs & Targets Jazz Pharmaceuticals and Zymeworks agree to develop, commercialize zanidatamab October 21, 2022Vol.48 No.38
Conversation with The Cancer Letter Fred Hutch receives $710.5M from Bezos family to speed up clinical trials, translational research, recruitmentGift is part of a 10-year $3B fundraising effort October 14, 2022Vol.48 No.37By Paul Goldberg
Guest Editorial What did we REALLY learn from the NordICC colonoscopy study? October 14, 2022Vol.48 No.37By William L. Dahut
